View More View Less
  • 1 Royal London Hospital, Pathology and Pharmacy Building Immunology Department 80 Newark Street, Whitechapel London E1 2ES UK
  • | 2 King’s College Hospital Department of Immunological Medicine London UK
  • | 3 Barts Health NHS Trust Immunology Department London UK
Open access

Pseudomonas aeruginosa (PA) is commonly isolated from the respiratory secretions of antibody deficiency patients, but the significance of this has not been well studied. We have reviewed our adult antibody deficiency cohort of 179 patients and assessed the prevalence and characteristics of PA infection and the effects of early antibiotic eradication treatments. Of the 34 patients with PA, 55.9% (19) underwent successful eradication and were infection-free, 38.2% (13) had intermittent infection, and 5.9% (2) had chronic PA. PA infection was significantly associated with bronchiectasis (p < 0.0001), with 36.1% (22 out of 61) of patients with bronchiectasis developing a PA infection. Infection status was also significantly associated with chronic sinusitis (p < 0.0001). Most treated PA exacerbations were symptomatic and with colony counts of ≥1000 cfu/ml. Current eradication protocols used at our center involve early treatment at first positive isolate with ciprofloxacin for 3 weeks and nebulized colomycin for 3 months, and if eradication fails, intravenous ceftazidime and gentamycin or colomycin is administered for 2 weeks. Continued sputum surveillance and early eradication treatments upon positive PA culture may help to limit chronic PA infection in antibody deficiency patients.

  • Cysticfibrosis.org: UK Cystic Fibrosis registry 2012 Annual Data Report. Bromley, Kent (2012)

    '', in UK Cystic Fibrosis registry 2012 Annual Data Report. Bromley, Kent , (2012 ) -.

  • Foundation CF: Cystic Fibrosis Foundation patient registry 2012 Annual Data Report. Bethesda, Maryland (2012)

    Foundation CF , '', in Cystic Fibrosis Foundation patient registry 2012 Annual Data Report. Bethesda, Maryland , (2012 ) -.

  • Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, et al.: Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293, 581–588 (2005)

    West SE , 'Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis ' (2005 ) 293 JAMA : 581 -588.

    • Search Google Scholar
  • Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J: Factors associated with lung function decline in adult patients with stable noncystic fibrosis bronchiectasis. Chest 132, 1565–1572 (2007)

    Soriano J , 'Factors associated with lung function decline in adult patients with stable noncystic fibrosis bronchiectasis ' (2007 ) 132 Chest : 1565 -1572.

    • Search Google Scholar
  • Wilson CB, Jones PW, O’Leary CJ, Hansell DM, Cole PJ, et al.: Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 10, 1754–1760 (1997)

    Cole PJ , 'Effect of sputum bacteriology on the quality of life of patients with bronchiectasis ' (1997 ) 10 Eur Respir J : 1754 -1760.

    • Search Google Scholar
  • Pettit SJ, Bourne H, Spickett GP: Survey of infection in patients receiving antibody replacement treatment for immune deficiency. J Clin Pathol 55, 577–580 (2002)

    Spickett GP , 'Survey of infection in patients receiving antibody replacement treatment for immune deficiency ' (2002 ) 55 J Clin Pathol : 577 -580.

    • Search Google Scholar
  • Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, et al.: X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 85, 193–202 (2006)

    Sullivan K , 'X-linked agammaglobulinemia: report on a United States registry of 201 patients ' (2006 ) 85 Medicine (Baltimore) : 193 -202.

    • Search Google Scholar
  • Frederiksen B, Koch C, Hoiby N: Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23, 330–335 (1997)

    Hoiby N , 'Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis ' (1997 ) 23 Pediatr Pulmonol : 330 -335.

    • Search Google Scholar
  • Hansen CR, Pressler T, Hoiby N: Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 7, 523–530 (2008)

    Hoiby N , 'Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience ' (2008 ) 7 J Cyst Fibros : 523 -530.

    • Search Google Scholar
  • Lee TW, Brownlee KG, Denton M, Littlewood JM, Conway SP: Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 37, 104–110 (2004)

    Conway SP , 'Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center ' (2004 ) 37 Pediatr Pulmonol : 104 -110.

    • Search Google Scholar
  • Pressler T, Bohmova C, Conway S, Dumcius S, Hjelte L, et al.: Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros 10(Suppl. 2), S75–78 (2011)

    Hjelte L , 'Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report ' (2011 ) 10 J Cyst Fibros : 75 -78.

    • Search Google Scholar
  • Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, et al.: Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 42, 249–255 (2007)

    Grasemann H , 'Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients ' (2007 ) 42 Pediatr Pulmonol : 249 -255.

    • Search Google Scholar
  • Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM: Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2, 29–34 (2003)

    Littlewood JM , 'Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients ' (2003 ) 2 J Cyst Fibros : 29 -34.

    • Search Google Scholar
  • Proesmans M, Balinska-Miskiewicz W, Dupont L, Bossuyt X, Verhaegen J, et al.: Evaluating the “Leeds criteria” for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J 27, 937–943 (2006)

    Verhaegen J , 'Evaluating the “Leeds criteria” for Pseudomonas aeruginosa infection in a cystic fibrosis centre ' (2006 ) 27 Eur Respir J : 937 -943.

    • Search Google Scholar
  • Pressler T, Karpati F, Granstrom M, Knudsen PK, Lindblad A, et al.: Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros 8, 37–42 (2009)

    Lindblad A , 'Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods ' (2009 ) 8 J Cyst Fibros : 37 -42.

    • Search Google Scholar
  • Ballmann M, Rabsch P, von der Hardt H: Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 53, 732–737 (1998)

    Hardt H , 'Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis ' (1998 ) 53 Thorax : 732 -737.

    • Search Google Scholar
  • Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, et al.: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16, 749–767 (2000)

    Hoiby N , 'Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus ' (2000 ) 16 Eur Respir J : 749 -767.

    • Search Google Scholar
  • Gathmann B, Grimbacher B, Beaute J, Dudoit Y, Mahlaoui N, et al.: The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol 157(Suppl. 1), 3–11 (2009)

    Mahlaoui N , 'The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008 ' (2009 ) 157 Clin Exp Immunol : 3 -11.

    • Search Google Scholar
The author instruction is available in PDF.
Please, download the file from HERE.
 

Senior editors

Editor(s)-in-Chief: Dunay, Ildiko Rita

Editor(s)-in-Chief: Heimesaat, Markus M.

Vice Editor(s)-in-Chief: Fuchs, Anja

Editorial Board

Chair of the Editorial Board:
Jeffrey S. Buguliskis (Thomas Jefferson University, USA)

  • Jörn Albring (University of Münster, Germany)
  • Stefan Bereswill (Charité - University Medicine Berlin, Germany)
  • Dunja Bruder (University of Megdeburg, Germany)
  • Jan Buer (University of Duisburg, Germany)
  • Jeff Buguliskis (Thomas Jefferson University, USA)
  • Edit Buzas (Semmelweis University, Hungary)
  • Charles Collyer (University of Sydney, Australia)
  • Renato Damatta (UENF, Brazil)
  • Ivelina Damjanova (Semmelweis University, Hungary)
  • Maria Deli (Biological Research Center, HAS, Hungary)
  • Olgica Djurković-Djaković (University of Belgrade, Serbia)
  • Jean-Dennis Docquier (University of Siena, Italy)
  • Anna Erdei (Eötvös Loránd University, Hungary)
  • Zsuzsanna Fabry (University of Washington, USA)
  • Beniam Ghebremedhin (Witten/Herdecke University, Germany)
  • Nancy Guillen (Institute Pasteur, France)
  • Georgina L. Hold (University of Aberdeen, United Kingdom)
  • Ralf Ignatius (Charité - University Medicine Berlin, Germany)
  • Zsuzsanna Izsvak (MDC-Berlin, Germany)
  • Achim Kaasch (University of Cologne, Germany)
  • Tamás Laskay (University of Lübeck, Germany)
  • Oliver Liesenfeld (Roche, USA)
  • Shreemanta Parida (Vaccine Grand Challenge Program, India)
  • Matyas Sandor (University of Wisconsin, USA)
  • Ulrich Steinhoff (University of Marburg, Germany)
  • Michal Toborek (University of Miami, USA)
  • Mary Jo Wick (University of Gothenburg, Sweden)
  • Susanne A. Wolf (MDC-Berlin, Germany)

 

Dr. Dunay, Ildiko Rita
Magdeburg, Germany
E-mail: ildikodunay@gmail.com

Indexing and Abstracting Services:

  • PubMed Central
  • Scopus
  • ESCI
  • CABI

 

2020  
CrossRef Documents 23
WoS Cites 708
Wos H-index 27
Days from submission to acceptance 219
Days from acceptance to publication 176
Acceptance Rate 70%

2019  
WoS
Cites
558
CrossRef
Documents
24
Acceptance
Rate
92%

 

European Journal of Microbiology and Immunology
Publication Model Gold Open Access
Submission Fee none
Article Processing Charge 928 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Gold Open Access
Purchase per Title  

European Journal of Microbiology and Immunology
Language English
Size A4
Year of
Foundation
2011
Publication
Programme
2021 Volume 11
Volumes
per Year
1
Issues
per Year
4
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2062-509X (Print)
ISSN 2062-8633 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
May 2021 0 6 1
Jun 2021 0 3 0
Jul 2021 0 6 4
Aug 2021 0 7 2
Sep 2021 0 1 1
Oct 2021 0 3 1
Nov 2021 0 0 0